精确瘤学的发展:药物重新发现协议 (DRUP) 的持续影响
Soemeya F Haj Mohammad1, Hans J L Timmer2, Laurien J Zeverijn3
1Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. s.f.haj_mohammad@lumc.nl.
药物重新发现协议 (DRUP) 试验为晚期癌症患者提供非标签向和免疫疗法. 虽然整体效益为33%,但特定的治疗方法表现出不同程度的成功,突出了精确瘤学.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 基因组学就是基因组学.
背景情况:
- 药物重新发现协议 (DRUP) 是一项荷兰的泛癌临床试验.
- 它专注于患有晚期或转移性癌症的患者,这些患者已经耗尽了标准治疗选择.
研究的目的:
- 调查用于非标签的向和免疫疗法的疗效和安全性.
- 为具有特定分子基因组变异的患者提供获得新型抗癌治疗的机会.
主要方法:
- 非随机临床试验设计.
- 患者的资格要求晚期癌症,没有标准选择,并且具有可向的分子基因组变异.
- 主要终点是临床益处,定义为客观反应或至少16周的稳定疾病.
主要成果:
- 在DRUP试验中,已有超过1500名患者接受治疗.
- 总体临床益处率 (CBR) 为33%.
- 尼沃卢马布在微卫星不稳定的瘤中显示出63%的CBR,而CDK4/6抑制剂的CBR为15%.
结论:
- 在荷兰和欧洲,DRUP成功地改善了患者获得非标签治疗的机会.
- 扩大类似的试验促进了精确瘤学和公平获得癌症治疗.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
相关概念视频
Drug Discovery: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
